Phase II genomics study of ixabepilone as neoadjuvant treatment for breast cancer.

J Clin Oncol 2009 Feb 15;27(4):526-34. Epub 2008 Dec 15.

Vall d'Hebron University Hospital, Barcelona, Spain.

Purpose: This phase II study evaluated the efficacy and safety of ixabepilone as neoadjuvant therapy for invasive breast cancer not amenable to breast conservation surgery. Gene expression studies were undertaken using genes that were identified as potentially associated with sensitivity/resistance to ixabepilone in prior preclinical investigations.

Patients And Methods: Patients with invasive breast cancer >or= 3 cm were eligible. Ixabepilone 40 mg/m(2) was administered as a 3-hour intravenous infusion on day 1 of a 21-day cycle for four or fewer cycles.

Results: One hundred sixty-one patients were treated. The overall complete pathologic response (pCR) rate was 18% in breast and 29% in estrogen receptor (ER) -negative patients. Gene expression data were available for 134 patients. ER gene expression (ER1) was inversely related to pCR in breast and had a positive predictive value (PPV) of 37% and negative predictive value (NPV) of 92%. A 10-gene penalized logistic regression (PLR) model developed from 200 genes predictive of ixabepilone sensitivity in preclinical experiments included ER and tau and had higher PPV (45%) and comparable NPV (89%) to ER1. Grade 3 to 4 adverse events (AEs) were reported for 32% of patients. Except for neutropenia and leukopenia, all grade 3 to 4 AEs occurred in
Results: indicate an inverse relation between ER expression levels and ixabepilone sensitivity. Neoadjuvant ixabepilone demonstrated promising activity and a manageable safety profile in patients with invasive breast tumors.

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2007.14.2646DOI Listing
February 2009
18 Reads

Publication Analysis

Top Keywords

breast cancer
12
gene expression
12
patients gene
8
invasive breast
8
ixabepilone neoadjuvant
8
breast
6
patients
5
ixabepilone
5
21-day cycle
4
regression plr
4
plr model
4
day 21-day
4
infusion day
4
model developed
4
cycle fewer
4
logistic regression
4
sixty-one patients
4
10-gene penalized
4
cyclesresults sixty-one
4
penalized logistic
4

Similar Publications